BIOPLUS-INTERPHEX KOREA 2025 – Seoul: Highlights and Event Recap

BIOPLUS-INTERPHEX KOREA was held in Seoul, Korea, from October 15 to October 17, 2025. The exhibition highlighted advances across the biopharmaceutical value chain and showcased the latest trends. 

Technology-focused topics included: 

• Antibody-Drug Conjugates (ADCs) & Biotherapeutics 

• Regenerative Medicine & Longevity 

• Digital Fill/Finish & Smart Manufacturing 

• Sustainable and Flexible Bioprocessing 

• AI, Cold-Chain & Materials Innovation 

→ Biointron’s Highlighted Points:

1. Antibody-Drug Conjugate (ADC) Development

• Ongoing ADC research focused on optimizing linkers, payload selection, and DAR control to balance potency with safety for solid-tumor targets. 

• Heterogeneity and manufacturability remain key challenges, with novel analytical workflows emerging for site-specific conjugation and structural characterization. 

• Discussions emphasized next-generation payloads and orthogonal QC strategies to enhance stability and therapeutic index. 

• The field is shifting toward platform-based ADC development, integrating machine learning for conjugation prediction and biophysical property optimization. 

2. Regenerative Medicine and Longevity

• Cellular and regenerative medicine were identified as cornerstones of next-generation therapeutics, extending beyond repair toward performance and resilience. 

• Research underscored the role of immune modulation and metabolic reprogramming in healthy aging and disease prevention. 

• Longevity biotechnology is increasingly viewed through a translational systems-biology lens, integrating stem-cell innovation with data-driven biomarker discovery. 

• The intersection of therapeutic biology and human enhancement marks the evolution of longevity as a medical and economic frontier. 

3. Anti-Aging: The Next Bio Frontier

• Anti-aging R&D is moving from topical applications to interventions targeting molecular hallmarks of aging, including DNA repair, senescence, and mitochondrial dynamics. 

• Experts highlighted the need for cross-disciplinary collaboration—where regulatory science, ethics, and market access must progress alongside biology. 

• Emerging tools in multi-omics and AI-guided modeling are enabling more precise target validation for age-modulating therapeutics. 

• The consensus: aging biology is the next frontier of biopharma innovation, poised to redefine preventive and restorative medicine. 

4. Digital and Automation Advances in Fill/Finish

• Virtual-reality and digital-twin systems are transforming fill/finish training, enabling immersive process simulation and minimizing operator deviation. 

• AI-driven in-line monitoring and automated data capture enhance process reliability and speed technology transfer across sites. 

• Integration of robotics and real-time visualization fosters a closed-loop, error-resilient fill/finish environment, setting new standards for compliance and agility.

5. Sustainable and Flexible Manufacturing

• Single-use bioreactor systems support sustainability goals while providing rapid product turnaround and scalability across modalities. 

• New bioprocess intensification strategies—combining perfusion culture, automation, and reduced-resource operations—lower carbon and water footprints. 

• The push toward eco-efficient design highlights that environmental responsibility and operational flexibility can be co-optimized in biologics production. 

6. Clinical Supply and Packaging Innovation

• Adaptive packaging solutions are being deployed to support global clinical agility and meet diverse regulatory requirements. 

• Real-time monitoring through IoT-enabled cold-chain systems ensures product stability throughout distribution. 

• Emerging packaging formats provide greater flexibility for RNA, cell, and antibody therapies, shortening timelines from clinical to commercial supply. 

7. Emerging Trends in Bio M·P·E, Cold Chain, and AI

• Rapid advances in bio-materials, parts, and equipment (M·P·E) strengthen regional self-sufficiency and production continuity. 

• Cold-chain modernization integrates predictive analytics and greener materials to reduce waste while maintaining biologic integrity. 

• AI applications now span from process optimization to predictive maintenance, establishing data-centric foundations for next-gen biomanufacturing.

Thank you to everyone who visited our booth at BIOPLUS-INTERPHEX KOREA 2025 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.